Can We Detect and Treat Alzheimer’s Disease a Decade Before the Onset of Dementia?


Can We Detect and Treat Alzheimer’s Disease a Decade Before the Onset of Dementia?

Reisa Sperling, MD, MMSC Professor of Neurology, Harvard Medical School

We invite you to join us on May 31st for the Distinguished Scientist Lecture featuring the work of Reisa Sperling, MD, MMSC. Dr. Sperling is the Director of the Harvard Center for Alzheimer's Research and Treatment, Director of Clinical Research for the Memory Disorders Unit at Brigham and Women's Hospital, and Director of the Neuroimaging Program at the Massachusetts Alzheimer's Disease Research Center at Brigham and Women’s Hospital. Her studies concentrates on the early diagnosis and treatment of Alzheimer's disease.

Dr. Reisa Sperling
                Reisa Sperling, MD, MMSC

Dr. Sperling is a neurologist focused on the early detection and treatment of Alzheimer’s disease, even before clinical symptoms are evident. Her research uses multi-modality neuroimaging and sensitive cognitive assessments to study the aging brain and the earliest changes associated with Alzheimer’s disease. She chaired the 2011 NIA-Alzheimer’s Association workgroup to develop guidelines for the study of “Preclinical Alzheimer’s disease.” Dr. Sperling leads the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s disease (A4) Study - a landmark secondary prevention trial in over 1,150 clinically normal older individuals with PET amyloid imaging evidence of early Alzheimer’s disease pathology, and the companion LEARN Study. In recognition of her many accomplishments, Dr. Sperling has been presented with numerous awards including the 2011 Derek Denny-Brown Young Neurological Scholar Award, the 2015 American Academy of Neurology Potamkin Prize, and was named one of the 2017 Most Disruptive Women to Watch in Healthcare.

Location. UPMC Western Psychiatric Hospital Auditorium.

For More Information. Please contact Frances Patrick (Telephone: 412-246-6787; Email:

Learning Objectives. At the conclusion of Dr. Sperling's lecture, attendees will be able to:


  1. Describe the preclinical stage of Alzheimer’s disease and risk of cognitive decline.

  2. Evaluate imaging and biomarker detection of early Alzheimer’s disease.

  3. Assess progress on ongoing Alzheimer prevention trials.

Continuing Education Credit:  The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  The University of Pittsburgh School of Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM.  Each physician should only claim credit commensurate with the extent of their participation in the activity.  Other health care professionals are awarded .15 continuing education units (CEUs), which are equal to 1.5 contact hours. In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, information about relationships of presenters with commercial interests (if any) will be included in materials which will be distributed at the time of the conference.  WPIC is approved by the American Psychological Association to offer continuing education for psychologists.  WPIC maintains responsibility for this program and its contents.  This program is being offered for 1.5 continuing education credits.
The indicated number of clock hours of continuing education is provided through Western Psychiatric Institute and Clinic of UPMC’s Office of Educational Resources and Planning, a PA-approved provider of social work continuing education in accordance with all the applicable educational and professional standards of the Pennsylvania State Board of Social Workers, Marriage and Family Therapist.  These clock hours satisfy requirements for LSW/LCSW, LPC and LMFT renewal. For more information, call (412) 204-9085.